Q-omics provides the consensus-scored CPHL1P profile across patient tissues and cancer cell-line models. CPHL1P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CPHL1P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CPHL1P RNA expression shows 11,271 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, KIRC, and BRCA as cancer lineages where CPHL1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPHL1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPHL1P survival associations across molecular data types. CPHL1P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPHL1P RNA expression–survival associations across cancer types. High CPHL1P expression shows unfavorable associations in KICH, KIRC, LIHC and LUAD, but favorable associations in HNSC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CPHL1P RNA expression.
This table summarizes CPHL1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CPHL1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPHL1P shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, LUAD, STAD and HNSC. The KIRC box plot shows higher CPHL1P RNA expression in tumor versus normal tissue (log2 FC = +0.322, t-test p < 0.001).
This table shows molecular features associated with CPHL1P in patient tissues and cancer cell lines. In patient samples, CPHL1P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
